Tafasitamab is a humanized monoclonal antibody that targets CD19. It is used for the treatment of B-cell malignancies. The CD19 surface protein is highly expressed on the surface of B-cells where it enhances B-cell receptor signaling. CD19 is especially expressed in cases of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL). By its activity, tafasatimab induces the lysis of B-cells.
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? *
Did it work in your application? *
Your review *
Save my name, email, and website in this browser for the next time I comment.
Got a question or need a quote? Message us and we’ll get back to you 48 hours or less.
Lab / Company
in 2023, NO price increase on ProteoGenix products, to support your discoveries💥